Background/Objectives: In recent years, silver complexes have shown strong antibacterial, antifungal, and antitumor activity with high selectivity toward cancer cells. Their cytotoxic effects are mainly linked to apoptosis induction, DNA damage, and enzyme inhibition, while the antitumor activity of silver(I) complexes with S-alkyl thiosalicylic acid derivatives remains unexplored. Methods: Silver(I) complexes with S-alkyl derivatives of thiosalicylic acid (C1–C5) were obtained through the direct reaction of silver(I) nitrate, the corresponding ligand of thiosalicylic acid, and a sodium hydroxide solution. The interactions between the complexes and CT-DNA/BSA were studied using UV-Vis, fluorescence spectroscopy, and molecular docking studies. The cytotoxic capacity of the newly synthesized complexes was assessed by an MTT assay. Results: Complexes C1–C5 exhibited strong cytotoxicity against murine and human breast (4T1, MDA-MB-468), colon (CT26, HCT116), and lung (LLC1, A549) cancer cell lines. The C3 complex significantly diminished tumor progression in an orthotropic mammary carcinoma model while demonstrating good systemic tolerance. Conclusions: The tested complex C3 triggered apoptosis in 4T1 cells by altering the delicate balance between pro- and anti-apoptotic Bcl-2 family members, increasing reactive oxygen species (ROS) levels, and reducing mitochondrial membrane depolarization. Moreover, the C3 arrested the 4T1 cell cycle in G0/G1 phase, decreasing the expression of cyclin D3 and increasing the expression of p16, p21, and p27.

Introduction. Deep vein thrombosis and pulmonary thromboembolism are among the most important causes of morbidity and mortality in cancer patients. They are common and serious complications that are affected by various risk factors. The aim of this study was to determine the incidence of thromboembolic complications and their association with risk factors in patients with newly diagnosed multiple myeloma. Material and Methods. A retrospective study included 32 patients and the following variables were collected: age, C-reactive protein, beta-2 microglobulin, hemoglobin, platelets, total proteins, nephrotic syndrome, fibrinogen, D-dimer, albumin, lactate dehydrogenase, creatinine, calcium, gender, performance status, type of multiple myeloma, clinical stage, and applied therapy. All variables were compared between two groups of patients: group with thromboembolic complications (deep venous thrombosis and pulmonary thromboembolism), and the group without these complications. Results. The study sample included 18 men and 14 women. The patients’ age ranged from 36 to 73 years. Of the 32 patients, 6 had deep venous thrombosis of the lower extremities, and 2 patients had deep venous thrombosis and pulmonary thromboembolism. The only two biomarkers that showed an association with venous thromboembolism in our patients with myeloma were elevated levels of C-reactive protein and D-dimer. Conclusion. The incidence of thromboembolic complications in patients with newly diagnosed multiple myeloma was 25%. When making the diagnosis of myeloma, risk factors that were significantly associated with venous thromboembolism were elevated levels of C-reactive protein and D-dimer. The occurrence of venous thromboembolism in patients with multiple myeloma was not associated with significantly higher mortality compared to patients without venous thromboembolism.

Background/Objectives: Silver has long been used in medicine for its diverse effects. Coordination of this metal ion with bioactive ligands such as thiosalicylic acid derivatives allows the synthesis of potentially promising antimicrobial and antitumor agents. Methods: The in vitro antimicrobial activity of silver(I) complexes (C1–C5) and their corresponding ligands (L1–L5) was determined using a resazurin-based microdilution method, while the inhibition of preformed biofilms was assessed against S. aureus, P. mirabilis, and P. aeruginosa. To explore the binding modes and affinity of the investigated silver(I) complexes, a molecular docking study was performed against the LasR transcriptional regulator, while in silico ADMET screening was conducted using the pkCSM online platform. Finally, the evaluation of in vitro immunomodulatory effects of the silver(I) complexes was assessed by measuring cytokine concentrations and performing flow cytometry. Results: In vitro and in silico evaluations confirm that the C2 complex possesses an optimal structural balance of size and hydrophobicity, enabling superior antimicrobial and antibiofilm activity against P. aeruginosa. Regarding the immune response, treatment with the C3 complex decreased the concentrations of the proinflammatory cytokines IL-1β, TNF-α, IL-6, and IL-12, while increasing the concentration of the anti-inflammatory cytokine IL-10 after LPS stimulation. Conclusions: Our findings demonstrate that C2 primarily targets bacterial pathogens, while C3 exerts potent immunomodulatory and anti-inflammatory effects that differ between innate and acquired, naïve and primed immune system cells. Therefore, investigating the combined or sequential application of C2 and C3 may provide a promising strategy for the treatment of chronic biofilm-associated infections.